Compugen Ltd. filed its third-quarter 2026 financial results on November 9, 2026, reporting a reduced net loss and providing a clinical and pipeline update covering COM701, rilvegostomig, GS-0321, and the newly introduced UnigenX discovery capability.

Key Highlights

  • MAIA-ovarian fully enrolled: The blinded, randomized trial enrolled 62 patients in a two-to-one ratio of COM701 to placebo, with results expected by end of Q1 2027, according to the filing.
  • Revenue nearly doubled year-over-year: Third-quarter 2026 revenues were approximately $3.8 million, compared with approximately $1.9 million in the third quarter of 2025.
  • Net loss narrowed: Net loss for Q3 2026 was approximately $5.8 million, or $0.06 per basic and diluted share, versus approximately $7.0 million, or $0.07 per basic and diluted share, in Q3 2025.
  • Cash position: As of September 30, 2026, the company held approximately $117.5 million in cash, cash equivalents, short-term bank deposits, and investments in marketable securities, with runway expected into 2029.
  • Rilvegostomig Phase 3 update: Partner AstraZeneca now anticipates high-level results from the ARTEMIDE-Biliary01 trial in the second half of 2027.
  • Gilead milestones: Compugen has received gross payments totaling $90 million from Gilead and remains eligible for up to $758 million in additional milestone payments, plus tiered royalties.
  • UnigenX introduced: Compugen disclosed a strategic expansion of its AI-powered discovery engine into tumor-associated antigens intended to support targeted immune activation modalities such as T cell engagers.

Compugen Reports Q3 2026 Financials and Clinical Pipeline Progress

Compugen Ltd. (NASDAQ:CGEN), listed on the Nasdaq exchange under ticker CGEN, reported third-quarter 2026 results on November 9, 2026. According to the filing, revenues for the quarter were approximately $3.8 million, up from approximately $1.9 million in the comparable 2025 period. The company disclosed that both figures reflect recognition of portions of the upfront payment and the investigational new drug milestone payment under its license agreement with Gilead. Research and development expenses were approximately $5.8 million for each of the third quarters of 2026 and 2025, while general and administrative expenses rose slightly to approximately $2.3 million from approximately $2.2 million in Q3 2025.

On the clinical front, the filing stated that MAIA-ovarian, a global, randomized, placebo-controlled adaptive platform trial evaluating COM701 as maintenance monotherapy in second- and third-line relapsed platinum-sensitive ovarian cancer, has completed enrollment at 62 patients. The company disclosed that it intends to evaluate the totality of the data, including "the magnitude and durability of separation between the COM701 and placebo arms and the proportion of patients remaining progression-free at six months." For rilvegostomig, an AstraZeneca-owned PD-1/TIGIT bispecific antibody whose TIGIT component is derived from Compugen's COM902, Phase 3 high-level results from the ARTEMIDE-Biliary01 trial are now anticipated in the second half of 2027. Compugen is eligible to receive up to $195 million in additional regulatory and commercial milestone payments, as well as up to mid-single-digit tiered royalties on future sales under its AstraZeneca license agreement, according to the filing.

The company also introduced UnigenX, described in the filing as a strategic expansion of its existing Unigen AI-powered discovery engine into tumor-associated antigens, intended to identify targets for modalities such as T cell engagers. The filing noted that Unigen has previously enabled the discovery of TIGIT, PVRIG, and IL-18BP as drug targets, all of which have progressed to clinical stage. The company's forward-looking statements, including expected trial timelines and cash runway, are the company's own and subject to its cautionary language as described in the filing.

What Was Disclosed

Compugen disclosed Q3 2026 financial results showing reduced net losses and higher revenues versus Q3 2025, confirmed full enrollment in MAIA-ovarian, updated the timeline for AstraZeneca's ARTEMIDE-Biliary01 Phase 3 results, and introduced the UnigenX discovery platform expansion.